Mesoblast Touts High Survival Rates For FDA-Approved Cell Therapy

Core Insights - Ryoncil has demonstrated high survival rates in patients with steroid-refractory acute graft-versus-host disease, highlighting the necessity for earlier intervention [1][5] Group 1: Ryoncil's Efficacy - Ryoncil (remestemcel-L-rknd) achieved high survival outcomes in both children and adults with steroid-refractory acute graft-versus-host disease, regardless of treatment line or patient resistance status [2] - In a study involving 53 patients with SR-aGvHD who received Ryoncil as a third-line treatment, 15% died before completing the treatment course, compared to only 2% in the Phase 3 trial when used as a second-line treatment [4] - The results underscore the importance of administering Ryoncil as early as possible after steroid resistance to maximize survival rates [5] Group 2: Regulatory Approval - Ryoncil is the first mesenchymal stromal cell product approved by the U.S. FDA for any indication and is the only product approved for children under age 12 with steroid-refractory acute graft-versus-host disease [3] Group 3: Market Performance - The stock is currently trading 1.8% above its 20-day simple moving average but 2.3% below its 50-day simple moving average, indicating short-term strength but medium-term resistance [6] - Over the past 12 months, shares have decreased by 1.29% and are closer to their 52-week highs than lows [6] - The RSI is at 54.28, indicating neutral territory, while the MACD is above its signal line, suggesting bullish momentum [7] Group 4: Price Action - Mesoblast shares were down 3.06% at $17.73 during premarket trading, with key resistance at $19.50 and key support at $17.50 [8]